ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
38.19
-0.10%
US Tech 100
19,486.00
-0.47%
S&P 500
5,738.50
-0.12%
US Dollar vs CAD
1.35137
0.27%
Bitcoin
65,878.96
1.07%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Alzamend Neuro Inc (ALZN)

  7. Alzamend Neuro Inc (ALZN) News

ALZN

Alzamend Neuro (ALZN)

Alzamend Neuro Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALZN
DateTimeSourceHeadlineSymbolCompany
09/11/20243:30PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALZNAlzamend Neuro Inc
08/26/20247:00AMBusiness WireAlzamend Neuro Issues Letter to StockholdersNASDAQ:ALZNAlzamend Neuro Inc
08/19/20247:00AMBusiness WireAlzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress DisorderNASDAQ:ALZNAlzamend Neuro Inc
08/12/20247:00AMBusiness WireAlzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder NASDAQ:ALZNAlzamend Neuro Inc
08/06/20247:00AMBusiness WireAlzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar DisorderNASDAQ:ALZNAlzamend Neuro Inc
08/05/20248:09AMBusiness WireAlzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer’s DiseaseNASDAQ:ALZNAlzamend Neuro Inc
07/31/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
07/31/20247:00AMBusiness WireAlzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price RequirementNASDAQ:ALZNAlzamend Neuro Inc
07/30/20243:30PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ALZNAlzamend Neuro Inc
07/30/20245:00AMEdgar (US Regulatory)Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405NASDAQ:ALZNAlzamend Neuro Inc
07/12/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
07/12/20247:00AMBusiness WireAlzamend Neuro Announces Reverse Stock SplitNASDAQ:ALZNAlzamend Neuro Inc
07/10/20247:52AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ALZNAlzamend Neuro Inc
07/09/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ALZNAlzamend Neuro Inc
07/08/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
06/11/20243:30PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ALZNAlzamend Neuro Inc
06/03/20243:30PMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:ALZNAlzamend Neuro Inc
05/31/20243:59PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ALZNAlzamend Neuro Inc
05/22/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
05/22/20247:00AMBusiness WireAlzamend Neuro Announces Favorable Decision from Nasdaq Hearings PanelNASDAQ:ALZNAlzamend Neuro Inc
05/16/20243:30PMEdgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:ALZNAlzamend Neuro Inc
05/14/20247:00AMBusiness WireAlzamend Neuro Announces Initial Closing of Private PlacementNASDAQ:ALZNAlzamend Neuro Inc
05/13/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
05/10/20244:06PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ALZNAlzamend Neuro Inc
05/10/20243:30PMEdgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ALZNAlzamend Neuro Inc
05/10/20245:30AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALZNAlzamend Neuro Inc
05/09/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
05/09/20243:20PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
05/09/20247:00AMBusiness WireAlzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 MillionNASDAQ:ALZNAlzamend Neuro Inc
05/07/20243:31PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALZNAlzamend Neuro Inc
 Showing the most relevant articles for your search:NASDAQ:ALZN

Your Recent History

LSE
BBEG
Jpm Bb Eur Gvt
USOTC
MSEXP
Middlesex Water (PK)
LSE
MY43
Citi Fun 25
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved